1018 ISS
drugOn this page
Also known as Cpg 1018Cpg oligonucleotide 1018 issCPG-1018Iss 1018Iss 1018 cpg oligodeoxynucleotideIss-1018
Summary
1018 Iss (CHEMBL4297680) is a phase-3 clinical-stage unknown; indicated across 5 conditions including severe acute respiratory syndrome and non-hodgkin lymphoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- Indications: 5 conditions
- Clinical trials: 2
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297680 |
| Name | 1018 ISS |
| Type | Unknown |
| Max phase | 3 |
Also known as: 1018 iss, 1018 ISS, Cpg 1018, Cpg oligonucleotide 1018 iss, CPG-1018, Iss 1018, Iss 1018 cpg oligodeoxynucleotide, Iss-1018
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
5 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| severe acute respiratory syndrome | 3 | MONDO:0005091 | MONDO:0100096 |
| non-Hodgkin lymphoma | 2 | MONDO:0018908 | EFO:0005952 |
| hepatitis B virus infection | 2 | MONDO:0005344 | EFO:0004197 |
| HIV infectious disease | 1 | MONDO:0005109 | EFO:0000764 |
| colorectal neoplasm | 1 | MONDO:0005335 | EFO:0004142 |
Clinical trials
Total trials: 2.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE2 | 1 |
| PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00251394 | PHASE2 | COMPLETED | Study of Dynavax’s 1018 ISS, Following Rituxan in Patients With B-Cell Follicular Lymphoma |
| NCT04177355 | PHASE1 | COMPLETED | Evaluating the Safety and Immunogenicity of HIV-1 BG505 SOSIP.664 gp140 With TLR Agonist and/or Alum Adjuvants in Healthy, HIV-uninfected Adults |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: severe acute respiratory syndrome